Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Stomach Neoplasms 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Colonic Neoplasms 3Burkitt Lymphoma 3Bile Duct Neoplasms 3Anus Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Testicular Neoplasms 2Prostatic Neoplasms 2Primary Myelofibrosis 2Neuroblastoma 2Neoplasms, Plasma Cell 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Multiple Myeloma 2Leukemia, Myeloid, Chronic-Phase 2

Interventions

pembrolizumab 60Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 27Carboplatin 26Irinotecan 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13Pemetrexed 13olaparib 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × Interleukin-12 Subunit p35 × Clear all
NCT03030378 2026-05-19

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
36 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡